Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Company Growth (employees)
Summit, US
Size (employees)
7,132 (est)+3%
Celgene Corporation was founded in 1986 and is headquartered in Summit, US

Key People at Celgene Corporation

Mark Alles

Mark Alles

Chief Executive Officer
Robert Hugin

Robert Hugin

Executive Chairman
Jacqualyn Fouse

Jacqualyn Fouse

President and Chief Operating Officer
Peter Kellogg

Peter Kellogg

Executive Vice President and Chief Financial Officer

Celgene Corporation Office Locations

Celgene Corporation has offices in Summit, Boudry, Singapore
Summit, US (HQ)
86 Morris Ave
Boudry, CH
1 Route de Perreux

Celgene Corporation Metrics

Celgene Corporation Financial Metrics

Revenue (2016)

$11.2 b

Revenue growth (2015-16), %


Gross profit

$10.8 b

Gross profit margin (2016), %


Net income (2016)

$2 b

Market capitalization (21-Mar-2017)

$98.5 b

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$6.2 b
Celgene Corporation's current market capitalization is $98.5 b.
Celgene Corporation's revenue was reported to be $11.2 b in FY, 2016 which is a 21.3% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$6.5 b$7.7 b$9.3 b$11.2 b

Revenue growth, %


Cost of goods sold

$340.4 m$385.9 m$420.1 m$438 m

Gross profit

$6.2 b$7.3 b$8.8 b$10.8 b

Gross profit Margin, %


Operating expense total

$4.7 b$5.2 b$7 b$8.1 b


$1.8 b$2.5 b$2.3 b$3.2 b

EBIT margin, %


Interest expense

$91.6 m$176.1 m$310.6 m$500.1 m

Pre tax profit

$1.7 b$2.3 b$2 b$2.4 b

Income tax expense

$215.5 m$327.5 m$421.5 m$373.3 m

Net Income

$1.4 b$2 b$1.6 b$2 b
FY, 2013FY, 2014FY, 2015FY, 2016


$3.2 b$4.1 b$4.9 b$6.2 b


$340.4 m$393.1 m$443.4 m$497.9 m

Current Assets

$7.6 b$9.7 b$9.4 b$10.9 b


$593.4 m$642.6 m$814.1 m$929.8 m


$2 b$2.2 b$4.9 b$4.9 b

Total Assets

$13.4 b$17.3 b$27.1 b$28.1 b

Accounts Payable

$156.2 m$198.2 m$240.8 m$247.1 m

Total Debt

$544.8 m$605.9 m$500.7 m

Current Liabilities

$1.9 b$2.1 b$2 b$3 b

Additional Paid-in Capital

$8.7 b$9.8 b$11.1 b$12.4 b

Retained Earnings

$4.5 b$6.5 b$8.1 b$10.1 b

Total Equity

$5.6 b$6.5 b$5.9 b$6.6 b

Debt to Equity Ratio

0.1 x0.1 x0.1 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

2.4 x2.7 x4.6 x4.3 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$1.4 b$2 b$1.6 b$2 b

Accounts Receivable

($101.4 m)($166.3 m)($304.7 m)($222.4 m)


($89.7 m)($56.5 m)($50.6 m)($55.3 m)

Cash From Operating Activities

$2.2 b$2.8 b$2.5 b$4 b

Capital Expenditures

($119.7 m)($150.3 m)($286.3 m)($236.2 m)

Cash From Investing Activities

($528.6 m)($1.4 b)($6.3 b)($1 b)

Long-term Borrowings

($513.9 m)

Cash From Financing Activities

($553.7 m)($417.4 m)$4.6 b($1.6 b)

Interest Paid

$90.8 m$196.2 m$243.3 m$527.2 m

Income Taxes Paid

$291.9 m$294.6 m$361.1 m$373 m

Free Cash Flow

$2.3 b$3 b$2.8 b$4.2 b

Celgene Corporation Market Value History

Celgene Corporation Median Salaries

Source: 55 public H-1B filings from Celgene Corporation

Celgene Corporation Online Presence

Celgene Corporation Company Life

You may also be interested in